For example, in a mouse model of multiple system atrophy, a synucleinopathy, a selective TLR4 agonist promoted microglial clearance of αSyn, while preventing αSyn-mediated TLR4 upregulation of proinflammatory cytokine secretion, resulting in neuroprotection and improved disease outcomes [171]. The gene discussed is TLR4; the disease is synucleinopathy.